Company Akebia Therapeutics, Inc.

Equities

AKBA

US00972D1054

Biotechnology & Medical Research

Market Closed - Nasdaq 04:00:00 2024-03-27 pm EDT Pre-market 08:00:10 am
2.24 USD +12.00% Intraday chart for Akebia Therapeutics, Inc. 2.685 +19.87%

Business Summary

Akebia Therapeutics, Inc. is an integrated biopharmaceutical company. The Company is focused on developing and commercializing therapeutics that serve as a foundation for future growth. The Company's portfolio includes Auryxia (ferric citrate), Vafseo (vadadustat), and HIF-PH inhibitors. Auryxia is a non-calcium, non-chewable, orally administered tablet, which controls the serum phosphorus levels in adult patients with dialysis-dependent chronic kidney disease, (DD-CKD), or the hyperphosphatemia Indication, and the treatment of iron deficiency anemia. Vafseo (vadadustat) is an oral hypoxia-inducible factor prolyl hydroxylase (HIF-PH) inhibitor, that is approved in Japan for the treatment of anemia due to chronic kidney disease (CKD), in adult patients. The Company utilizes third parties for the commercial distribution of Auryxia, including wholesale distributors and certain specialty pharmacy providers.

Number of employees: 167

Sales per Business

USD in Million2022Weight2023Weight Delta
Novel Therapeutics
100.0 %
292 100.0 % 195 100.0 % -33.46%

Sales per region

USD in Million2022Weight2023Weight Delta
United States
100.0 %
292 100.0 % 195 100.0 % -33.46%

Managers

Managers TitleAgeSince
Chief Executive Officer 59 13-06-30
Chief Administrative Officer - 22-03-31
Chief Operating Officer 45 12-12-31
Chief Tech/Sci/R&D Officer 63 19-06-16
Chief Tech/Sci/R&D Officer - -
Corporate Officer/Principal - -
General Counsel - 20-12-31
Human Resources Officer - 22-04-30
Corporate Officer/Principal - -
Corporate Officer/Principal 54 Jan. 08

Members of the board

Members of the board TitleAgeSince
Director/Board Member 64 18-12-11
Chairman 73 18-12-11
Director/Board Member 65 21-02-15
Chief Executive Officer 59 13-06-30
Director/Board Member 71 18-12-11
Director/Board Member 65 21-10-31
Director/Board Member 55 18-08-27
Director/Board Member 53 20-04-05

Share class

VoteQuantityFree-FloatCompany-owned sharesTotal Float
Stock A 1 209,372,275 187,778,075 ( 89.69 %) 0 89.69 %

Shareholders

NameEquities%Valuation
Alerce Investment Management LP
6.132 %
11,552,558 6.132 % 18 M $
Vanguard Global Advisers LLC
4.038 %
7,607,472 4.038 % 12 M $
Acadian Asset Management LLC
3.671 %
6,915,503 3.671 % 11 M $
Renaissance Technologies LLC
2.537 %
4,779,383 2.537 % 8 M $
4,652,561 2.470 % 7 M $
Millennium Management LLC
1.380 %
2,599,987 1.380 % 4 M $
BlackRock Institutional Trust Co. NA
1.335 %
2,514,860 1.335 % 4 M $
2,364,436 1.255 % 4 M $
Susquehanna Securities LLC
1.146 %
2,159,364 1.146 % 3 M $
Jacobs Levy Equity Management, Inc.
0.9857 %
1,856,925 0.9857 % 3 M $

Company contact information

Akebia Therapeutics, Inc.

245 First Street Suite 1400

02142, Cambridge

+617 871 2098

http://www.akebia.com
address Akebia Therapeutics, Inc.(AKBA)